CRL News and Press, Charles River Laboratories International Inc. From 11/26/23

2023-11-26 09:13:34 ET Summary Charles River Laboratories provides essential products and services to accelerate research and drug development efforts. The company benefits from competitive advantages thanks to the entry barriers, since its clients usually opt for suppliers with g...

New option for cryopreserved leukopaks supports demand of gene-modified cell therapy development and manufacturing Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its CliniPrime™ suite of Good Manufacturing Practice (GMP)-compliant ...

Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an equity investment in Aitia as part of the agreement Charles River Laboratories International, Inc. (NYSE: CRL) and Aitia , ...

2023-11-09 18:19:22 ET Summary Charles River Laboratories' shares have fallen 21% this year and dropped 4% after a mixed earnings report. The company beat earnings expectations but revised its revenue growth and EPS guidance downward. Charles River is struggling to secure new ...

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 19 scientific posters, both independently and collaboratively with clients, at Neuroscience 2023, the annual meeting of the Society for Neuroscience (SfN). ...

2023-11-08 11:17:02 ET Charles River Laboratories International, Inc. (CRL) Q3 2023 Earnings Conference Call November 08, 2023 08:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chairman, President & Chief Executive Of...

2023-11-08 07:01:17 ET More on Charles River Laboratories Charles River Laboratories: Diving Into The Lab (Rating Upgrade) Charles River Laboratories Q3 2023 Earnings Preview Charles River falls on Investor Day amid growth concerns Seeking Alpha’s Quan...

– Third-Quarter Revenue of $1.03 Billion – – Third-Quarter GAAP Earnings per Share of $1.69 and Non-GAAP Earnings per Share of $2.72 – – Updates 2023 Guidance – Charles River Laboratories International, Inc. (NYSE: CRL) today...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Charles River Laboratories International Inc. (CRL) is expected to report $2.35 for Q3 2023